SpringerLink
Log in

Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Aim of this study is to evaluate the outcome of long-term conservative treatment with sulindac and high-dose selective estrogen receptor modulators (SERMs) for sporadic and FAP-associated desmoid tumors. Desmoids are very rare tumors in the general population but occur frequently in FAP patients, being encountered in 23–38 %. Treatment of desmoids is still most controversial since response cannot be predicted and they are prone to develop recurrence. This study included all desmoid patients that were treated and followed at our institution and had completed at least 1 year of treatment. Response was defined as stable size or regression of desmoid size between two CT or MRI scans. A total of 134 patients were included. 64 (47.8 %) patients had a confirmed diagnosis of FAP, 69 (51.5 %) patients were sporadic. Overall 114 (85.1 %) patients showed regressive or stable desmoid size. Patients with previous history of multiple desmoid-related surgeries showed less-favorable response. The mean time to reach at least stable size was 14.9 (±9.1) months. After regression or stabilization, medication was tapered in 69 (60.5 %) of the treated patients with only one long-term recurrence after >10 years. The results of this study fortify the role of sulindac and high-dose SERMs as an effective and safe treatment for both, sporadic and FAP-associated desmoid tumors. While invasive treatment frequently results in high recurrence rates, high morbidity and high mortality, this conservative treatment is successful in most patients. The recurrence rate is negligible with no desmoid-related mortality in this large series. Therefore surgical resection, especially for mesenteric desmoids, should be deferred favoring this convincingly effective, well tolerated regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Robanus-Maandag E, Bosch C, Amini-Nik S, Knijnenburg J, Szuhai K, Cervera P et al (2011) Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids. PLoS One 6(9):e24354

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Litchman C (2012) Introduction. In: Litchman C (ed) Desmoid tumors. Springer, Dordrecht, pp 1–2

    Chapter  Google Scholar 

  3. Church JM (1995) Desmoid tumors in patients with familial adenomatous polyposis. Semin Colon Rectal Surg 6(1):29–32

    Google Scholar 

  4. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G (2004) High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100(3):612–620

    Article  PubMed  CAS  Google Scholar 

  5. Vasen HFA, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57(5):704–713

    Article  PubMed  CAS  Google Scholar 

  6. Garzón-Benavides M, Pizarro-Moreno A, García-Lozano R, Herrero-Garrido MI, Hervás-Molina AJ, Márquez-Galán JL et al (2010) Andalusian registry for familial adenomatous polyposis. Analysis of patients included. Rev Esp Enferm Dig 102(11):653–657

    Article  PubMed  Google Scholar 

  7. Friedl W, Caspari R, Sengteller M, Uhlhaas S, Lamberti C, Jungck M et al (2001) Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 48(4):515–521

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Sinha A, Tekkis PP, Gibbons DC, Phillips RK, Clark SK (2011) Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 13(11):1222–1229

    Article  PubMed  CAS  Google Scholar 

  9. Knudsen AL, Bülow S (2000) Desmoid tumor in familial adenomatous polyposis. Ugeskr Laeg 162(42):5628–5631

    PubMed  CAS  Google Scholar 

  10. Sturt NJH, Gallagher MC, Bassett P, Philp CR, Neale KF, Tomlinson IPM et al (2004) Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 53(12):1832–1836

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Nieuwenhuis MH, Lefevre JH, Bülow S, Järvinen H, Bertario L, Kernéis S et al (2011) Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum 54(10):1229–1234

    Article  PubMed  Google Scholar 

  12. Church J (2012) Desmoid disease in familial adenomatous polyposis. In: Litchman C (ed) Desmoid tumors. Springer, Dordrecht, p 147

    Chapter  Google Scholar 

  13. Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P et al (2003) Multiple approach to the exploration of genotype–phenotype correlations in familial adenomatous polyposis. J Clin Oncol 21(9):1698–1707

    Article  PubMed  CAS  Google Scholar 

  14. Lynch HT, Fitzgibbons R Jr (1996) Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature review. Am J Gastroenterol 91(12):2598–2601

    PubMed  CAS  Google Scholar 

  15. Zeng W-G, Zhou Z-X, Liang J-W, Hou H-R, Wang Z, Zhou H-T et al (2014) Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution. Tumour Biol 35(8):7513–7521

    Article  PubMed  CAS  Google Scholar 

  16. Reitamo JJ, Scheinin TM, Häyry P (1986) The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 151(2):230–237

    Article  PubMed  CAS  Google Scholar 

  17. Reitamo JJ, Häyry P, Nykyri E, Saxén E (1982) The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol 77(6):665–673

    PubMed  CAS  Google Scholar 

  18. Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF (1989) The desmoid tumor. Not a benign disease. Arch Surg 124(2):191–196

    Article  PubMed  CAS  Google Scholar 

  19. Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJ, Booker SV et al (1994) Desmoid tumours in familial adenomatous polyposis. Gut 35(3):377–381

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Nieuwenhuis MH, Cappel WDVTN, Botma A, Nagengast FM, Kleibeuker JH, Mathus-Vliegen EMH et al (2008) Desmoid tumors in a dutch cohort of patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 6(2):215–219

    Article  PubMed  Google Scholar 

  21. Bertario L, Russo A, Sala P, Eboli M, Giarola M, D’amico F et al (2001) Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 95(2):102–107

    Article  PubMed  CAS  Google Scholar 

  22. Durno C, Monga N, Bapat B, Berk T, Cohen Z, Gallinger S (2007) Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastroenterol Hepatol 5(10):1190–1194

    Article  PubMed  Google Scholar 

  23. Schiessling S, Kihm M, Ganschow P, Kadmon G, Büchler MW, Kadmon M (2013) Desmoid tumour biology in patients with familial adenomatous polyposis coli. Br J Surg 100(5):694–703

    Article  PubMed  CAS  Google Scholar 

  24. Nieuwenhuis MH, Casparie M, Mathus-Vliegen LMH, Dekkers OM, Hogendoorn PCW, Vasen HFA (2011) A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer 129(1):256–261

    Article  PubMed  CAS  Google Scholar 

  25. Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF (1999) The enigma of desmoid tumors. Ann Surg 229(6):866–872 (discussion 872-873)

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Caspari R, Olschwang S, Friedl W, Mandl M, Boisson C, Böker T et al (1995) Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 4(3):337–340

    Article  PubMed  CAS  Google Scholar 

  27. Davies DR, Armstrong JG, Thakker N, Horner K, Guy SP, Clancy T et al (1995) Severe Gardner syndrome in families with mutations restricted to a specific region of the APC gene. Am J Hum Genet 57(5):1151–1158

    PubMed  CAS  PubMed Central  Google Scholar 

  28. Church J, Xhaja X, LaGuardia L, O’Malley M, Burke C, Kalady M (2015) Desmoids and genotype in familial adenomatous polyposis. Dis Colon Rectum 58(4):444–448

    Article  PubMed  Google Scholar 

  29. Stoeckle E, Coindre JM, Longy M, Binh MBN, Kantor G, Kind M et al (2009) A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol 35(2):129–134

    Article  PubMed  CAS  Google Scholar 

  30. Latchford AR, Sturt NJH, Neale K, Rogers PA, Phillips RKS (2006) A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Br J Surg 93(10):1258–1264

    Article  PubMed  CAS  Google Scholar 

  31. Lahat G, Nachmany I, Itzkowitz E, Abu-Abeid S, Barazovsky E, Merimsky O et al (2009) Surgery for sporadic abdominal desmoid tumor: Is low/no recurrence an achievable goal? ISR Med Assoc J 11(7):398–402

    PubMed  Google Scholar 

  32. Berk T, Cohen Z, McLeod RS, Stern HS (1992) Management of mesenteric desmoid tumours in familial adenomatous polyposis. Can J Surg 35(4):393–395

    PubMed  CAS  Google Scholar 

  33. Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C et al (2009) Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 16(9):2587–2593

    Article  PubMed  Google Scholar 

  34. Shido Y, Nishida Y, Nakashima H, Katagiri H, Sugiura H, Yamada Y et al (2009) Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Trauma Surg 129(7):929–933

    Article  PubMed  Google Scholar 

  35. Kasper B, Ströbel P, Hohenberger P (2011) Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist 16(5):682–693

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  36. Nuyttens JJ, Rust PF, Thomas CR Jr, Turrisi AT 3rd (2000) Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 88(7):1517–1523

    Article  PubMed  CAS  Google Scholar 

  37. Garbay D, Le Cesne A, Penel N, Chevreau C, Marec-Berard P, Blay J-Y et al (2012) Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 23(1):182–186

    Article  PubMed  CAS  Google Scholar 

  38. Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM et al (2010) Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 16(19):4884–4891

    Article  PubMed  CAS  Google Scholar 

  39. Leithner A, Schnack B, Katterschafka T, Wiltschke C, Amann G, Windhager R et al (2000) Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. J Surg Oncol 73(1):21–25

    Article  PubMed  CAS  Google Scholar 

  40. Gounder MM, Lefkowitz RA, Keohan ML, D’Adamo DR, Hameed M, Antonescu CR et al (2011) Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 17(12):4082–4090

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  41. Clark SK, Neale KF, Landgrebe JC, Phillips RK (1999) Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 86(9):1185–1189

    Article  PubMed  CAS  Google Scholar 

  42. Bocale D, Rotelli MT, Cavallini A, Altomare DF (2011) Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis 13(12):e388–e395

    Article  PubMed  CAS  Google Scholar 

  43. Colombo C, Foo WC, Whiting D, Young ED, Lusby K, Pollock RE et al (2012) FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. Histol Histopathol 27(5):641–649

    PubMed  Google Scholar 

  44. Tsukada K, Church JM, Jagelman DG, Fazio VW, McGannon E, George CR et al (1992) Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 35(1):29–33

    Article  PubMed  CAS  Google Scholar 

  45. Belliveau P, Graham AM (1984) Mesenteric desmoid tumor in Gardner’s syndrome treated by sulindac. Dis Colon Rectum 27(1):53–54

    Article  PubMed  CAS  Google Scholar 

  46. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L Jr (2000) Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 95(1):104–110

    Article  PubMed  CAS  Google Scholar 

  47. Shanle EK, Xu W (2010) Selectively targeting estrogen receptors for cancer treatment. Adv Drug Deliv Rev 62(13):1265–1276

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  48. Brooks MD, Ebbs SR, Colletta AA, Baum M (1992) Desmoid tumours treated with triphenylethylenes. Eur J Cancer 28A(6–7):1014–1018

    Article  PubMed  CAS  Google Scholar 

  49. Lackner H, Urban C, Kerbl R, Schwinger W, Beham A (1997) Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer 80(2):334–340

    Article  PubMed  CAS  Google Scholar 

  50. Bauernhofer T, Stöger H, Schmid M, Smola M, Gürtl-Lackner B, Höfler G et al (1996) Sequential treatment of recurrent mesenteric desmoid tumor. Cancer 77(6):1061–1065

    Article  PubMed  CAS  Google Scholar 

  51. Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ (1983) Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 52(12):2201–2204

    Article  PubMed  CAS  Google Scholar 

  52. Tonelli F, Ficari F, Valanzano R, Brandi ML (2003) Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori 89(4):391–396

    PubMed  CAS  Google Scholar 

  53. Leithner A, Gapp M, Radl R, Pascher A, Krippl P, Leithner K et al (2005) Immunohistochemical analysis of desmoid tumours. J Clin Pathol 58(11):1152–1156

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  54. Deyrup AT, Tretiakova M, Montag AG (2006) Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer 106(1):208–213

    Article  PubMed  CAS  Google Scholar 

  55. Santos GAC, Cunha IW, Rocha RM, Mello CAL, Guimarães GC, Fregnani JH et al (2010) Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options. Biosci Trends 4(1):25–30

    PubMed  CAS  Google Scholar 

  56. Lim CL, Walker MJ, Mehta RR, Gupta TK (1986) Estrogen and antiestrogen binding sites in desmoid tumors. Eur J Cancer Clin Oncol 22(5):583–587

    Article  PubMed  CAS  Google Scholar 

  57. Benson JR, Baum M (1993) Breast cancer, desmoid tumours, and familial adenomatous polyposis—a unifying hypothesis. Lancet 342(8875):848–850

    Article  PubMed  CAS  Google Scholar 

  58. Moeslein G (2006) Invited commentary. Fam Cancer 5(3):287–288

    Article  Google Scholar 

  59. Colombo C, Miceli R, Le Péchoux C, Palassini E, Honoré C, Stacchiotti S et al (2015) Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer 51(2):186–192

    Article  PubMed  CAS  Google Scholar 

  60. Desurmont T, Lefèvre JH, Shields C, Colas C, Tiret E, Parc Y (2015) Desmoid tumour in familial adenomatous polyposis patients: responses to treatments. Fam Cancer 14(1):31–39

    Article  PubMed  CAS  Google Scholar 

  61. Quintini C, Ward G, Shatnawei A, Xhaja X, Hashimoto K, Steiger E et al (2012) Mortality of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis: a single center review of 154 patients. Ann Surg 255(3):511–516

    Article  PubMed  Google Scholar 

  62. Bonvalot S, Ternès N, Fiore M, Bitsakou G, Colombo C, Honoré C et al (2013) Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol 20(13):4096–4102

    Article  PubMed  Google Scholar 

  63. Quast D, Schneider C, Burdzik E, Möslein G (2011) Abstracts of 2011 InSiGHT-Meeting: long-term outcome of FAP-associated and sporadic desmoid tumours in 154 patients. Fam Cancer 10(4):713–743

    Article  Google Scholar 

  64. Skapek SX, Anderson JR, Hill DA, Henry D, Spunt SL, Meyer W, et al. (2012) Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) Phase II Study. Pediatr Blood Cancer 60(7):1108–1112

    Article  PubMed  PubMed Central  Google Scholar 

  65. Honeyman JN, Theilen T-M, Knowles MA, McGlynn MM, Hameed M, Meyers P et al (2013) Desmoid fibromatosis in children and adolescents: a conservative approach to management. J Pediatr Surg 48(1):62–66

    Article  PubMed  Google Scholar 

  66. Burgess A, Xhaja X, Church J (2011) Does intra-abdominal desmoid disease affect patients with an ileal pouch differently than those with an ileorectal anastomosis? Dis Colon Rectum 54(11):1388–1391

    Article  PubMed  CAS  Google Scholar 

  67. Lazar AJF, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E et al (2008) Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173(5):1518–1527

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  68. Bo N, Wang D, Wu B, Chen L, Ma R (2011) Analysis of β-catenin expression and exon 3 mutations in pediatric sporadic aggressive fibromatosis. Pediatr Dev Pathol [Internet]. [cited 2012 Aug 9]; http://www.ncbi.nlm.nih.gov/pubmed/21323417

  69. Matono H, Tamiya S, Yokoyama R, Saito T, Iwamoto Y, Tsuneyoshi M et al (2011) Abnormalities of the Wnt/β-catenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between β-catenin widespread nuclear expression and VEGF overexpression. Histopathology 59(3):368–375

    Article  PubMed  Google Scholar 

  70. Kattentidt Mouravieva AA, Geurts-Giele IRR, de Krijger RR, van Noesel MM, van de Ven CP, van den Ouweland AMW et al (2012) Identification of familial adenomatous polyposis carriers among children with desmoid tumours. Eur J Cancer 48(12):1867–1874

    Article  PubMed  Google Scholar 

  71. Mullen JT, DeLaney TF, Rosenberg AE, Le L, Iafrate AJ, Kobayashi W et al (2013) β-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist 18(9):1043–1049

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Allgemeine Innere Medizin - Medizinische Klinik I, St. Josef-Hospital, Gudrunstr. 56, 44791, Bochum, Germany

    Daniel Robert Quast

  2. Klinik für Hereditäre Tumorerkrankungen, HELIOS-Klinikum Wuppertal, Heusnerstr. 40, 42283, Wuppertal, Germany

    Ralph Schneider & Gabriela Möslein

  3. Klinik für Allgemein- und Viszeralchirurgie, Evangelisches Krankenhaus Bethesda zu Duisburg, Heerstraße 219, 47053, Duisburg, Germany

    Emanuel Burdzik

  4. Klinik für Radiologie, HELIOS St. Josefs-Hospital Bochum-Linden, Axstr. 35, 44879, Bochum, Germany

    Steffen Hoppe

Authors
  1. Daniel Robert Quast
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralph Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emanuel Burdzik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steffen Hoppe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gabriela Möslein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Robert Quast.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quast, D.R., Schneider, R., Burdzik, E. et al. Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients. Familial Cancer 15, 31–40 (2016). https://doi.org/10.1007/s10689-015-9830-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-015-9830-z

Keywords

Search

Navigation